๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 23 Beijing 20 Guangzhou 14 Hangzhou 13 Tianjin 8
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai23 Beijing20 Guangzhou14 Hangzhou13 Tianjin8
All 38 locations
Target enrolment
to

Trials with a site in Beijing

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
NCT07560124Breast Cancer
Akeso
Phase 1/2
286
Beijing, Harbin, Chengdu
2026-06-06
Not yet open
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis
NCT07436234Seasonal Allergic Rhinitis
DrugAK139
Akeso
Phase 2
111
Beijing
2026-03-02
Recruiting
A Study of Ivonescimab in First-Line ES-SCLC
NCT07245446Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Akeso
Phase 2
180
Beijing, Xi'an, Shanghai
2025-10-29
Recruiting
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
NCT07023315Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Akeso
Phase 3
760
Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin
2025-08-14
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263Small Cell Lung Cancer
Akeso
Phase 3
560
Beijing, Beijin, Chongqing, Fuzhou, Longyan, Zhangzhou, Lanzhou, Jiangmen
2025-06-13
Recruiting
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
NCT06938321Biliary Tract Cancer
Akeso
Phase 1/2
135
Beijing
2025-04-30
Not yet open
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
NCT06767540Atopic Dermatitis
Akeso
Phase 3
198
Wuhu, Beijing, Chongqing, Dongguan, Guangzhou, Jiangmen, Shenzhen, Zhuhai
2025-01-23
Recruiting
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
NCT06642792Classic Hodgkin Lymphoma
Akeso
Phase 1/2
280
Beijing
2025-01-17
Recruiting
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
NCT07547787Locally Advanced Unresectable or Metastatic Gastric Cancer
Akeso
Observational
610
Beijing
2024-12-26
Recruiting
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT06530251Hepatocellular Carcinoma
Akeso
Phase 1/2
280
Beijing, Jinan
2024-09-24
Recruiting
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06341335Gastric and Gastroesophageal Junction Adenocarcinoma
Akeso
Phase 3
506
Beijing
2024-06-19
Not yet open
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127Locally Advanced or Metastatic NSCLC
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
NCT05689853Solid Tumor, Adult
Akeso
Phase 1/2
87
Beijing
2023-04-14
Recruiting
A Study of AK129 in Patients With Advanced Malignant Tumors
NCT05645276Advanced Malignant Tumors(Stage IA-IB)
Akeso
Phase 1
182
Beijing
2023-03-02
Active, closed
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma
Akeso
Phase 2
60
Beijing, Guangzhou, Zhengzhou, Changsha, Jinan
2022-06-28
Active, closed
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
NCT05235516Locally Advanced Cervical Carcinoma
Akeso
Phase 3
636
Beijing, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2022-06-21
Recruiting
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
NCT04982276Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Akeso
Phase 1/2
138
Beijing
2021-08-23
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

13 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 20 studies
PhaseStudiesRecruitingShare
Phase 38440%
Phase 1/26530%
Phase 24220%
Observational115%
Phase 1115%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Akeso2013
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.